Almost Day after day, this keeps going up.

What happens is there are lots of small shareholders selling out during the day who probably bought in when it was 25p due to being tipped in shares mag in July

THEN

At the end of each day there is a really BIG BUY that most people don't notice.
Usually at 16:29.

Next morning, it usually opens up 1/4p

This keeps on happening.

I finally freed up some cash this morning & bought some.
I wish that I had got in at 17p.

The big buyers obviously think that the new drugs will ge a great success.

What do you think?


It was also tipped again in October

SHARES MAGAZINE 30-10-2003

The gene therapy specialist has had a good run this year with shares rising to 28.2p in September. The company has two cancer therapies in the clinic for a range of indications as well as early-stage drugs for neurological disorders.

TroVax is a revolutionary cancer vaccine that works by delivering a gene to the cancer cell via a pox virus acting as a Trojan horse. The drug is in Phase II trials in colorectal cancer patients with the kudos of being sponsored by Cancer Research UK and trials in breast and renal cancer patients. MetXia has also received approval to enter Phase I/II trials for pancreatic cancer.

Investors should recall the high failure rate of cancer drugs such as British Biotechs Marimastat and remember that the risks are high, but Oxford Biomedica is well funded following a recent fundraising and there is still everything to play for.

http://www.wallstreetreporter.com/profiles/OxfordBioMedica.html

Yes, they have got more as they had just over 9% previously

Thanks Janus.

One or two institutions dipping their toe into the OXB water, I hear.

Roll on Wednesday and Final Results. Should be interesting to see what AK has to say.

Just at the level of breakout as I write this.

Looks good for wednesday

Yes, we're off the blocks today, Apple - as you say, looks good for Wednesday.

Daily Express.
Share whisper: OXFORD BIOMEDICA (gossips reckon the company could announce a further licensing seal for its LentiVector gene delivery system along with figures soon)

Morning All - Not too sure about whispers in the Daily Express - but with two days to go all positive news is good.

Morning Oakapples142

It's 1 day not 2.

Results tomorrow!

I feel there may be an announcement of a deal tomorrow, without it the results may look uninteresting but the outlook should be good.

Thanks Apple - I`ll take another bite ! -

Hope so robstuff

We even hit 30p for a while this morning.

Yeah, it hit 30p for 1st time and the sellers didn't materialise, MMs reduced price though, not sure why.

I suggest (and hope!) that reduced price is intended for a negotiating large purchase at the end of play

I suppose they were just trying to shake out a few weak holders.

Final results

http://www.uk-wire.com/cgi-bin/articles/200403030700110626W.html

Results, steady progress as expected so the MMs opened it down & are getting some stock.

The new licencing deal talked about in the Express will, if true be announced when the deal is done. Pity it wasn't in time for the results but hey it gives the directors another buying opportunity :-)

just had some time to digest the results/outlook and gosh! what a lot of info.! I always think that's a good sign and the info given really shows the incredible amount of things going on with this co. Perhaps we shareholders get impatient and lose interest but this field was always going to be LONG term and the foundations are now there... newsflow is important and we may see some ups and downs waiting for it but i'm in for the long term and over time this co. is going from strength to stenghth, nothings going to happen overnight but once results of trials start coming in and more licensing deals, it'll be harder and harder to pick these up cheap. a steady rise in share price over the yr with a few set backs I would expect. Oxf bio now a major force in the race to beat cancer and the rewards to those who stay with it should be BIG.

FROM SEYMOUR PIERCE

* SALES WERE IN LINE WITH OUR FORCAST OF 0.4M, HOWEVER DUE TO LOWER ADMINISTRATION EXPENSES AND GRANTS/GOVERNMENT RESEARCH CONTRIBUTIONS, PRE TAX PROFIT WAS AHEAD BY 900K. THE COMPANY ALSO RECORDED A 1.2M TAX CREDIT. CASH STANDS AT 31.8M, ENOUGH FOR 3 YEARS AT THE CURRENT BURN RATE IN THE ABSENCE OF ANY LICENSING INCOME.

* THE CLINICAL PIPELINE REMAINS BROAD AND DEEP. TROVAX IS IN 5 PHASE 11 TRIALS ACROSS A SERIES OF CANCERS AND IS EXPECTED TO REPORT DATA OVER THE NEXT 12-18 MONTHS. OXFORD BIOMEDICA IS FUNDING THREE OF THE TRIALS, 2 COLORECTAL AND ONE RENAL STUDY. A FURTHER COLORECTAL STUDY IS SPONSORED BY CANCER RESEARCH UK AND THE SOUTHWEST ONCOLOGY GROUP, PART OF NCI, IS TO FUND A STAGE 111/1V OPEN LABEL BREAST CANCER STUDY IN 120 PATIENTS. RECRUITMENT IS EXPECTED TO START IN Q3 2004.

* THE TARGETED ANTIBODY THERAPY STUDT WITH WYETH SUCCESSFULLY COMPLETED ITS PRE CLINICAL PROGRAMME TO THE SATISFACTION OF WYETH, WHICH TRIGGERED A MILESTONE PAYMENT. a FURTHER PAYMENT IS EXPECTED WHEN THE PRODUCT ENTERS THE CLINIC, WHICH WE WOULD EXPECT DURING 2004.

* METXIA COMPLETED TWO STUDYS (PHASE1/11) IN A TOTAL OF 19 PATIENTS DEMONSTRATING SAFETY AND EFFICACY. ANECDOTALLY A COLLATERAL IMMUNE RESPONSE WAS OBSERVED IN SEVERAL PATIENTS, WHEREBY SURFACE TUMOUR NOT TREATED DIRECTLY WITH METXIA WAS SEEN TO DISAPEAR.

* THE PRE-CLINICAL NEUTOTHERAPY PORTFOLIO CONTINUED TO PROGRESS. PROSAVIN, THE PARKINSON`S TREATMENT, IS EXPECTED TO ENTER THE CLINIC LATER THIS YEAR AFTER PRODUCING VERY ENCOURAGING DATA IN PRE-CLINICAL MODELS CLOSELT ALIGNED TO AND HIGHLY PREDICTIVE OF THE HUMAN FORM. HOWEVER, THIS PROGRAMME IS ABOUT 6 MONTHS BEHIND.

* LOOKING FORWARD WE EXPECT REGULAR CLINICAL NEWSFLOW FROM TROVAX AND METXIA, ENTRY OF PROSAVIN INTO THE CLINIC AND A MILESTONE PAYMENY ASSOCIATED WITH THE PROGRESS OF THE WYETH COLLABORATION.

* IN THE SHORT TERM FURTHER REVENUE COULD BE DERIVED FROM FURTHER LICENSE DEALS ALONG THE LINES OF THE MERCK DEAL ANNOUNCE IN FEBRUARY.

* OVERALL WE STILL SEE A COMPELLING ARGUMENT TO INVEST IN OXB, IT HAS A STRONG PIPELINE RETAINING MUCH OF THE IP AND THREE YEARS CASH, WHICH SHOULD GIVE THEM A SIGNIFICANT ADVANTAGE IN LICENSE DISCUSSIONS. WE REITERATE OUR 33P PRICE TARGET. BUY

Interesting! Thank's for this Janus. Price has settled, may drop a touch tomorrow but my bet is that it'll recover quickly with institutional interest and more Buy recommendations.

Managad to sell my extra 5,400 when the price blipped up yesterday which enabled me to buy back 5,000 GFM. First time I've been able to catch a price blip like that. Still holding my original 10,000 though - won't let those go!
I really want this company to suceed and beat this terrible disease once and for all then we can all breathe a sigh of relief.